7Wire Ventures outlines how diagnostics, biotechnology, AI, and digital platforms collaborate to shift the focus from lifespan to healthspan, using biomarker tracking and preventive interventions to keep individuals active and disease-free.
Key points
- Consumer Diagnostics & Care draws $3.5B in funding for at-home biomarker testing platforms like Superpower Health, enabling personalized longevity insights.
- AI-driven drug discovery by firms such as BioAge Labs uses longitudinal human data to uncover aging targets, accelerating therapeutic development.
- Cellular Rejuvenation ventures like Altos Labs pursue partial reprogramming of aged cells to restore youthful function and tissue resilience.
Why it matters: Emphasizing healthspan through preventive, data-driven approaches promises to transform healthcare into a proactive system that improves quality of life and reduces overall costs.
Q&A
- What is the difference between lifespan and healthspan?
- How do longevity biomarkers work?
- Why isn’t aging recognized as a disease by regulators?
- What role does AI play in drug discovery for aging?
- How can consumers access longevity services today?
